CompletedPhase 2ACTRN12614001108606

Quercetin supplementation in adolescents with familial hypercholesterolaemia (FH)

The effect of quercetin supplementation in adolescents with familial hypercholesterolaemia (FH) on flow mediated dilatation of the brachial artery


Sponsor

Dr Andrew Martin

Enrollment

10 participants

Start Date

Nov 3, 2014

Study Type

Interventional

Conditions

Summary

This project aims to investigate the potential beneficial effect of a natural plant food compound (quercetin), on blood vessel function in adolescents with Familial Hypercholesterolaemia (FH). FH is a common genetic disorder affecting many thousands of children and adolescents throughout Australia, that elevates blood cholesterol from the time of birth, predisposing them to heart disease in early adult life. Untreated, 50% of men and 20% of women will have suffered a fatal or non-fatal cardiovascular event (ie heart attack) by the age of 50. Children with FH have highly compromised blood vessel function. Whilst medications like statins will lower cholesterol levels and can help improve blood vessel function, there is general reluctance among physicians and parents to commence children with FH on statins before the age of 18 years, because of a lack of long-term follow up studies on the use of these medications in younger patients. Thus, a nutrition-based supplement that could improve blood vessel function in children and adolescents with FH prior to them going on long term statin therapy would be of benefit. Using non-invasive ultrasound, we will investigate the effect of consuming a drink containing the natural plant food compound quercetin on how the blood vessel functions in 10 adolescents with FH aged 13-18 years. This will be compared to a placebo drink that contains a harmless sugar compound. We expect that the plant food compound will have a beneficial effect on blood vessel function in this population and lead to a potential new treatment option.


Eligibility

Sex: Both males and femalesMin Age: 13 YearssMax Age: 18 Yearss

Inclusion Criteria1

  • Adolescents with familial hypercholesterolaemia

Exclusion Criteria1

  • Participant or legal guardian/parent unable to provide an informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Following an overnight fast, participants will undergo baseline measurements of endothelial function, before receiving oral quercetin aglycone (300mg dissolved in water). There will be a 7-day washout

Following an overnight fast, participants will undergo baseline measurements of endothelial function, before receiving oral quercetin aglycone (300mg dissolved in water). There will be a 7-day washout period between the intervention and control.


Locations(1)

Princess Margaret Hospital - Subiaco

WA, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12614001108606


Related Trials